Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

被引：0
|
作者：
Reimann, Patrick [1 ,2 ]
Winder, Thomas [1 ,3 ]
机构：
[1] Feldkirch Acad Teaching Hosp, Dept Internal Med 2, Carinagasse 47, A-6800 Feldkirch, Austria
[2] Private Univ Principal Liechtenstein, Triesen, Liechtenstein
[3] Univ Zurich, Zurich, Switzerland
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2023年 / 16卷 / 04期
关键词：
Pancreatic cancer treatment; Primary resectable cancer; Metastatic; Neoadjuvant therapy; First-line treatment; PHASE-II; FOLFIRINOX;
D O I：
10.1007/s12254-023-00931-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this short review, we aim to summarize the essential news and highlights in pancreatic cancer that were presented at ASCO 2023. We focus in particular on primary resectable as well as advanced or metastatic disease. Therefore, the first results of the NORPACT-1 trial and the updated data from the NAPOLI-3 study are summarized. We discuss these studies and their potential influence on daily clinical practice with regard to current standard of care.
引用
收藏
页码：225 / 229
页数：5
相关论文
共 50 条
  • [21] Radiochemotherapy in advanced Pancreatic cancer primarily non-resectable
    Messmer, M-B
    Thomsen, A. R.
    Knippen, S.
    Momm, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 112 - 112
  • [22] The surgical outcomes of borderline resectable or locally advanced pancreatic cancer
    Okamura, Yukiyasu
    Sugiura, Teiichi
    Ito, Takaaki
    Yamamoto, Yusuke
    Ashida, Ryo
    Ohgi, Katsuhisa
    Uesaka, Katsuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [23] Some More News on the Metastatic Pathway in Pancreatic Cancer
    Uomo, Generoso
    JOURNAL OF THE PANCREAS, 2005, 6 (01): : 42 - 46
  • [24] Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer
    Scheufele, Florian
    Hartmann, Daniel
    Friess, Helmut
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 4
  • [25] Is neoadjuvant chemotherapy the optimal treatment for primary resectable pancreatic cancer?
    Wang, Yu-song
    HPB, 2020, 22 (05) : 790 - 790
  • [26] Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update: ASCO Guideline Q and A
    Virgo, Katherine S.
    Rumble, R. Bryan
    Talcott, James A.
    JCO ONCOLOGY PRACTICE, 2023, 19 (10)
  • [27] FOLFIRINOX in locally advanced or metastatic pancreatic cancer
    Faris, Jason Edward
    Hong, Theodore S.
    McDermott, Shaunagh
    Guimaraes, Alexander R.
    Sahani, Dushyant
    Clark, Jeffrey W.
    Ryan, David P.
    Blaszkowsky, Lawrence Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [28] ROLE OF CHEMOTHERAPY IN ADVANCED OR METASTATIC NON-RESECTABLE GASTRIC CANCER
    Badulescu, F.
    Schenker, M.
    Ionescu, M.
    Ninulescu, G.
    Badulescu, A.
    Dinescu, S.
    ANNALS OF ONCOLOGY, 2009, 20 : 81 - 81
  • [29] Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
    Maggino, Laura
    Malleo, Giuseppe
    Marchegiani, Giovanni
    Viviani, Elena
    Nessi, Chiara
    Ciprani, Debora
    Esposito, Alessandro
    Landoni, Luca
    Casetti, Luca
    Tuveri, Massimiliano
    Paiella, Salvatore
    Casciani, Fabio
    Sereni, Elisabetta
    Binco, Alessandra
    Bonamini, Deborah
    Secchettin, Erica
    Auriemma, Alessandra
    Merz, Valeria
    Simionato, Francesca
    Zecchetto, Camilla
    D'Onofrio, Mirko
    Melisi, Davide
    Bassi, Claudio
    Salvia, Roberto
    JAMA SURGERY, 2019, 154 (10) : 932 - 942
  • [30] Current therapy concepts for primarily resectable and locally advanced pancreatic cancer
    D'Haese, J. G.
    Heinemann, V.
    Belka, C.
    Werner, J.
    ONKOLOGE, 2015, 21 (11): : 1032 - 1043
12345